Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Dupixent Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Dupixent (dupilumab) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA coverage and prior authorization requirements for Dupixent in FDA-approved and compendial indications for QUEST members, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, and immune checkpoint inhibitor-related toxicities.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyDupixent (dupilumab) Coverage and Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJuly 1, 2026
    Next Review DateN/A
    Key ActionSubmit the prior authorization request with indication-specific clinical documentation before review.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7FDA-approved indications
    8Covered indication categories
    6 monthsYoungest coverage age
    12 monthsMaximum authorization period
    300 cells/microliterCOPD eosinophil threshold
    Not allowedSame-indication concomitant therapy

    Coverage Criteria

    Initial therapy: Atopic dermatitis

    Authorization of 4 months may be granted when ONE of the following pathways is met.

    Qualifying pathway

    • Recent qualifying therapy: Member is at least 6 months of age and previously received a biologic or systemic targeted synthetic drug indicated for moderate-to-severe atopic dermatitis within the past 180 days.Age >= 6 months; within past 180 days
    • Disease severity and topical therapy

      • Disease extent: Affected body surface area is at least 10% or crucial body areas are affected.BSA >= 10%

        Crucial areas include the hands, feet, face, neck, scalp, genitals/groin, and intertriginous areas.

      • Prior topical therapy

        • Inadequate response to a high- or super-high-potency topical corticosteroid for 2 consecutive weeks, topical calcineurin inhibitor for 6 consecutive weeks, topical JAK inhibitor for 8 consecutive weeks, and topical aryl hydrocarbon receptor agonist for 8 consecutive weeks.2/6/8/8 consecutive weeks
        • Therapies not advisable: The specified high- or super-high-potency topical corticosteroid, topical calcineurin inhibitor, topical JAK inhibitor, and topical aryl hydrocarbon receptor agonist are not advisable because of contraindication, intolerance, age-related potency concerns, or other clinical reason.

    Initial therapy: Asthma

    Authorization of 6 months may be granted when ONE of the following pathways is met.

    Qualifying pathway

    • Recent qualifying therapy: Member is at least 6 years of age and previously received a biologic drug indicated for asthma within the past year.Age >= 6 years; within past year
    • Uncontrolled asthma and optimized treatment

      • Uncontrolled asthma: Within the past year, the member had at least two exacerbations requiring oral or injectable corticosteroids, at least one exacerbation requiring hospitalization or emergency medical care, or poor symptom control with frequent symptoms or reliever use, activity limitation, or nighttime waking.
      • Treatment pathway

    Initial therapy: Chronic rhinosinusitis with nasal polyposis

    Authorization of 6 months may be granted when ONE of the following pathways is met.

    Qualifying pathway

    • Recent qualifying therapy: Member is at least 12 years of age and previously received a biologic indicated for chronic rhinosinusitis with nasal polyposis within the past year.Age >= 12 years; within past year
    • CRSwNP clinical pathway: Member is at least 12 years of age and has bilateral nasal polyposis with chronic sinusitis symptoms despite at least 4 weeks of intranasal corticosteroid treatment unless contraindicated or not tolerated; prior sino-nasal surgery or ineffective systemic corticosteroid treatment within the last 2 years unless contraindicated or not tolerated; a qualifying objective polyp finding; nasal blockage, congestion, or obstruction plus rhinorrhea, reduced/lost smell, or facial pain/pressure; and will continue daily intranasal corticosteroid therapy unless contraindicated or not tolerated.Intranasal corticosteroid >= 4 weeks; Meltzer score >= 2 in both nostrils or total NPS >= 5 with >= 2 per nostril

    Initial therapy: Eosinophilic esophagitis

    Authorization of 6 months may be granted when ALL of the following are met.

    Member is at least 1 year old and weighs at least 15 kg; has symptoms of esophageal dysfunction; has biopsy-confirmed eosinophilic esophagitis with at least 15 intraepithelial esophageal eosinophils per high-power field; and has inadequate response to a proton pump inhibitor or swallowed topical corticosteroid unless contraindicated or not tolerated.Age >= 1 year; weight >= 15 kg; biopsy count >= 15 eosinophils/high-power field

    Symptoms may include dysphagia, food impaction, vomiting, abdominal pain, food refusal, or failure to thrive.

    Initial therapy: Prurigo nodularis

    Authorization of 6 months may be granted when ONE of the following pathways is met.

    Qualifying pathway

    • Recent qualifying therapy: Member is at least 18 years old and previously received a biologic indicated for prurigo nodularis within the past year.Age >= 18 years; within past year
    • Clinical and prior-treatment pathway: Member is at least 18 years old, has pruritus lasting at least 6 weeks, a history or signs of repeated itch-scratch behavior, at least 20 nodular lesions, and either inadequate response to one specified therapy or intolerance or a clinical reason to avoid the specified topical or systemic therapy combinations.Pruritus >= 6 weeks; >= 20 nodular lesions

      Specified treatments include topical corticosteroids, topical calcineurin inhibitor, phototherapy, methotrexate, and cyclosporine.

    Initial therapy: Chronic obstructive pulmonary disease

    Authorization of 12 months may be granted when ONE of the following pathways is met.

    Qualifying pathway

    • Recent qualifying therapy: Member is at least 18 years old and previously received a biologic indicated for COPD within the past year.Age >= 18 years; within past year
    • COPD clinical pathway: Member is at least 18 years old; diagnosis is confirmed by post-bronchodilation FEV1/FVC less than 0.7; the member has classic COPD signs or symptoms; absolute blood eosinophil count is at least 300 cells per microliter before treatment; qualifying moderate or severe exacerbations occurred in the last year; the member is receiving qualifying maintenance inhaled therapy; and will continue maintenance COPD treatment with Dupixent.FEV1/FVC < 0.7; eosinophils >= 300 cells/microliter; 2 moderate or 1 severe exacerbation

    Initial therapy: Chronic spontaneous urticaria

    Authorization of 6 months may be granted when ONE of the following pathways is met.

    Qualifying pathway

    • Recent qualifying therapy: Member is at least 12 years old and previously received a biologic indicated for chronic spontaneous urticaria within the past year.Age >= 12 years; within past year
    • Clinical pathway: Member is at least 12 years old, remains symptomatic despite up-dosing a second-generation H1 antihistamine for at least 2 weeks, has been evaluated for other causes of wheals or angioedema, and has spontaneous wheals, angioedema, or both for at least 6 weeks.H1 antihistamine up-dosing >= 2 weeks; symptoms >= 6 weeks

    Initial therapy: Immune checkpoint inhibitor-related toxicity

    Authorization of 12 months may be granted when ONE of the following pathways is met.

    Qualifying toxicity pathway

    • Dupixent is used for severe grade 3 immune checkpoint inhibitor-related pruritus after no response to gabapentinoids for one month.G3 pruritus; gabapentinoid trial for 1 month
    • Dupixent is used as additional therapy for bullous pemphigoid with moderate grade 2 bullous dermatitis, or for severe grade 3 or life-threatening grade 4 bullous dermatitis.G2 bullous pemphigoid, or G3/G4 bullous dermatitis

    Moderate-to-severe atopic dermatitis

    Reauthorization of 12 months may be granted for a member previously authorized by HMSA/CVS when the following is met.

    Member is at least 6 months of age and achieves or maintains a positive clinical response, evidenced by low disease activity such as clear or almost clear skin, or improvement in redness, itching, or oozing/crusting.Age >= 6 months

    Prior HMSA/CVS authorization is required.

    Asthma

    Reauthorization of 12 months may be granted when ALL of the following are met.

    ALL of the following

    • Member is at least 6 years of age and asthma control has improved on Dupixent, demonstrated by reduced frequency or severity of symptoms or exacerbations, or reduced daily maintenance oral corticosteroid dose.Age >= 6 years
    • Member will continue an inhaled corticosteroid and an additional controller in combination with Dupixent.

    Chronic rhinosinusitis with nasal polyposis

    Reauthorization of 12 months may be granted when ALL of the following are met.

    ALL of the following

    • Member is at least 12 years of age and has achieved or maintained a positive clinical response, including improvement in nasal congestion, polyp size, loss of smell, rhinorrhea, sinonasal inflammation, hyposmia, facial pressure or pain, or reduction in corticosteroid use.Age >= 12 years
    • Member will continue daily intranasal corticosteroid therapy unless contraindicated or not tolerated.

    Eosinophilic esophagitis

    Reauthorization of 12 months may be granted when the following are met.

    Member is at least 1 year old, weighs at least 15 kg, was previously authorized by HMSA/CVS, and has achieved or maintained a positive clinical response evidenced by improvement in dysphagia, heartburn, chest pain, or emesis.Age >= 1 year; weight >= 15 kg

    Prurigo nodularis

    Reauthorization of 12 months may be granted when the following are met.

    Member is at least 18 years old, was previously authorized by HMSA/CVS, and has achieved or maintained a positive clinical response evidenced by low disease activity such as clear or almost clear skin, or reduced pruritus intensity with improvement in the extent and severity of nodular lesions.Age >= 18 years

    Chronic obstructive pulmonary disease

    Reauthorization of 12 months may be granted when ALL of the following are met.

    ALL of the following

    • Member is at least 18 years old and has achieved or maintained a positive clinical response or disease stabilization, evidenced by decreased exacerbations, improved pre-bronchodilator FEV1, or stabilization of disease.Age >= 18 years
    • Member will continue maintenance COPD treatment, such as ICS with LAMA and LABA, or LAMA and LABA, in combination with Dupixent.

    Chronic spontaneous urticaria

    Reauthorization of 12 months may be granted for a member previously authorized by HMSA/CVS when the following is met.

    Member is at least 12 years old and has experienced a positive clinical response since initiation of therapy, such as improved symptoms or a decrease in weekly urticaria activity score (UAS7).Age >= 12 years

    Immune checkpoint inhibitor-related toxicities

    Reauthorization of 12 months may be granted for a member previously authorized by HMSA/CVS when the applicable pathway is met.

    ANY of the following

    • Member was previously authorized for severe grade 3 pruritus and achieves or maintains a positive clinical response evidenced by low disease activity or improvement in signs and symptoms.G3 pruritus
    • Member was previously authorized for bullous dermatitis and achieves or maintains a positive clinical response, with either moderate grade 2 bullous dermatitis when the diagnosis is bullous pemphigoid, or severe grade 3 or life-threatening grade 4 bullous dermatitis.G2 bullous pemphigoid, or G3/G4 bullous dermatitis

    General requirements

    For all indications, the following restriction applies.

    Member does not use another biologic drug or targeted synthetic drug concomitantly with Dupixent for the same indication.No same-indication concomitant biologic or targeted synthetic drug

    Applies to all indications.

    Dupixent is not indicated for relief of acute bronchospasm, treatment of status asthmaticus, or treatment of other forms of urticaria.

    For any covered indication, Dupixent must not be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Initial Therapy Criteria

    Atopic dermatitis — qualifying initial therapy pathways

    Atopic dermatitis has TWO qualifying initial-therapy pathways.

    ONE of

    • Member is at least 6 months of age and previously received a qualifying biologic or systemic targeted synthetic drug for moderate-to-severe atopic dermatitis within the past 180 days.Age >= 6 months; within past 180 days
    • Member has affected body surface area of at least 10% or crucial body areas affected, and within the past 365 days had inadequate response to all specified topical therapies or those therapies are not advisable.BSA >= 10% or crucial body area; prior therapy within 365 days

      Specified therapies are high- or super-high-potency topical corticosteroid, topical calcineurin inhibitor, topical JAK inhibitor, and topical aryl hydrocarbon receptor agonist.

    Chronic rhinosinusitis with nasal polyposis — qualifying initial therapy pathways

    Continuation and Reauthorization Criteria

    Continuation therapy — positive clinical response or improved disease control requirements

    Continuation requests require documentation of positive clinical response or improved disease control appropriate to the indication.

    Indication-specific response

    • Positive clinical response is documented for atopic dermatitis, CRSwNP, EoE, prurigo nodularis, COPD, or immune checkpoint inhibitor-related toxicity.
    • Improved asthma control is documented, including reduced symptoms or exacerbations or reduced maintenance oral corticosteroid dose.
    • Positive response to therapy is documented for CSU.

    Moderate-to-severe atopic dermatitis — continuation criteria

    Authorization of 12 months may be granted after prior HMSA/CVS authorization.

    Clinical Thresholds and Coding Details

    Atopic dermatitis affected area
    Affected area thresholdAt least 10% body surface area or crucial body areas affected
    Crucial body areasHands, feet, face, neck, scalp, genitals/groin, and intertriginous areas
    Applicable conditionModerate-to-severe atopic dermatitis
    Asthma baseline blood eosinophil count
    Baseline eosinophil thresholdAt least 150 cells per microliter
    Required contextAsthma remains inadequately controlled despite optimized medium-to-high-dose inhaled corticosteroid and an additional controller
    Phenotype

    Provider Submission and Review Requirements

    Prior Authorization

    Prior Authorization Submission: Clinical Documentation

    Submit the clinical information required to initiate prior authorization review, including indication-specific chart notes, medical records, or claims history. Documentation must support diagnosis, disease severity, prior treatment, clinical response, and continuation requirements, as applicable to the requested indication.

    Prior Authorization

    Specialist Prescriber Requirement

    Dupixent must be prescribed by or in consultation with an eligible specialist for the requested indication.

    • Dermatologist: atopic dermatitis, prurigo nodularis, immune checkpoint inhibitor-related toxicity, or chronic spontaneous urticaria.
    • Allergist/immunologist: atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, COPD, or CSU.
    • Pulmonologist: asthma or COPD.
    • Otolaryngologist: CRSwNP.
    • Gastroenterologist: EoE.

    Policy Background

    Dupixent (dupilumab) is authorized for multiple type 2 inflammatory and immune-mediated conditions, including moderate-to-severe atopic dermatitis, eosinophilic or oral corticosteroid-dependent asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, eosinophilic-phenotype chronic obstructive pulmonary disease, and chronic spontaneous urticaria. The policy also recognizes immune checkpoint inhibitor-related toxicities as a compendial use.

    Covered indications have age- and clinical-specific requirements. Examples include atopic dermatitis in patients 6 months and older, asthma beginning at 6 years, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria beginning at 12 years, eosinophilic esophagitis beginning at 1 year and weighing at least 15 kg, and adult-only use for prurigo nodularis and COPD. Coverage is indication-specific and generally requires documented disease severity, inadequate response or inappropriateness of prior therapy, and continued clinical benefit.

    Clinical Definitions

    Asthma eosinophilic phenotype
    Qualifying thresholdBaseline blood eosinophil count of at least 150 cells per microliter
    Control requirementAsthma remains inadequately controlled despite optimized medium-to-high-dose inhaled corticosteroid and an additional controller
    Additional controller examplesLong-acting beta2-agonist, long-acting muscarinic antagonist, leukotriene modifier, or sustained-release theophylline
    Spirometric COPD confirmation
    Confirmation thresholdFEV1/FVC less than 0.7
    Measurement timingPost-bronchodilation spirometry
    Diagnostic use

    Step Therapy Requirements

    ConditionRequired prior therapyDuration or exception
    Atopic dermatitisInadequate response to all four: high- or super-high-potency topical corticosteroid; topical calcineurin inhibitor; topical JAK inhibitor; and topical aryl hydrocarbon receptor agonist.2 consecutive weeks for corticosteroid; 6 consecutive weeks for calcineurin inhibitor; 8 consecutive weeks each for topical JAK inhibitor and aryl hydrocarbon receptor agonist. Therapy may be omitted when not advisable because of contraindication, intolerance, age-related potency concerns, or inadequate response. A qualifying biologic or systemic targeted synthetic drug within the past 180 days is an alternative pathway.
    ConditionRequired prior therapyDuration or exception
    AsthmaInadequate control despite optimized inhaled corticosteroid plus an additional controller, with either qualifying eosinophilic disease or oral corticosteroid dependence.Eosinophilic pathway: medium-to-high-dose inhaled corticosteroid plus an additional controller and baseline eosinophils of at least 150 cells per microliter. Oral corticosteroid-dependent pathway: high-dose inhaled corticosteroid, additional controller, and prednisone/prednisolone or equivalent at least 5 mg daily. Inhaled corticosteroid and controller should be used for at least 3 months; oral glucocorticoids for most days during the prior 6 months.
    ConditionRequired prior therapyDuration or exception
    Chronic rhinosinusitis with nasal polyposis (CRSwNP)Persistent symptoms despite intranasal corticosteroid therapy, plus prior sino-nasal surgery or ineffective systemic corticosteroid treatment.Intranasal corticosteroid therapy for at least 4 weeks. Systemic corticosteroid treatment must have been within the last 2 years when used for the alternative pathway. Requirements may be excepted when treatment is contraindicated or not tolerated; daily intranasal corticosteroid therapy continues during treatment unless similarly excepted.
    ConditionRequired prior therapyDuration or exception
    Eosinophilic esophagitis (EoE)Inadequate response to either a proton pump inhibitor or swallowed topical corticosteroid therapy.No specific treatment duration stated. Prior therapy may be omitted when contraindicated or not tolerated.
    ConditionRequired prior therapyDuration or exception
    Prurigo nodularisInadequate response to at least one of: medium- to super-high-potency topical corticosteroid, topical calcineurin inhibitor, phototherapy, methotrexate, or cyclosporine; or intolerance or clinical reason to avoid specified topical or systemic treatment combinations.No specific duration stated for prior therapies. Pruritus must have lasted at least 6 weeks. Avoidance may apply to the topical corticosteroid plus topical calcineurin inhibitor combination or the methotrexate plus cyclosporine combination.
    ConditionRequired prior therapyDuration or exception
    Chronic obstructive pulmonary disease (COPD)Current maintenance inhaled triple therapy consisting of ICS, LAMA, and LABA; or LAMA plus LABA when ICS is contraindicated. Continue maintenance COPD treatment with Dupixent.Qualifying exacerbations must have occurred within the last year. Maintenance treatment must continue in combination with Dupixent.
    ConditionRequired prior therapyDuration or exception
    Chronic spontaneous urticaria (CSU)Remain symptomatic despite up-dosing a second-generation H1 antihistamine.At least 2 weeks of up-dosed therapy. Member must also have spontaneous wheals, angioedema, or both for at least 6 weeks and evaluation for other causes.
    ConditionRequired prior therapyDuration or exception
    Immune checkpoint inhibitor-related pruritusNo response to gabapentinoids before Dupixent authorization.Severe grade 3 pruritus; gabapentinoids must be tried for one month without response.

    Authorization Periods and Quantity Limits

    Dupixent 4-month authorization quantity limit
    Authorization period4 months per course
    Applicable indicationAtopic dermatitis
    MedicationDupixent
    Dupixent 6-month authorization quantity limit
    Authorization period6 months per course
    Applicable indicationsAsthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic spontaneous urticaria
    Medication
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyDupixent (dupilumab) Coverage and Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJuly 1, 2026
    Next Review DateN/A
    Key ActionSubmit the prior authorization request with indication-specific clinical documentation before review.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Reauthorization CriteriaClinical Thresholds and Coding DetailsProvider Submission and Review RequirementsPolicy BackgroundClinical DefinitionsStep Therapy RequirementsAuthorization Periods and Quantity Limits
    Eosinophilic phenotype:
    Baseline blood eosinophil count is at least 150 cells per microliter and asthma remains inadequately controlled despite optimized medium-to-high-dose inhaled corticosteroid and an additional controller.
    Eosinophils >= 150 cells/microliter
  1. Oral corticosteroid-dependent asthma: Asthma remains inadequately controlled despite optimized high-dose inhaled corticosteroid, an additional controller, and oral glucocorticoids of at least 5 mg/day of prednisone, prednisolone, or equivalent.Oral glucocorticoids >= 5 mg/day; used most days during prior 6 months
  2. Maintenance therapy: Member will continue maintenance asthma treatment with an inhaled corticosteroid and an additional controller in combination with Dupixent.
  3. CRSwNP has TWO qualifying initial-therapy pathways.

    ONE of

    • Member is at least 12 years of age and previously received a biologic indicated for CRSwNP within the past year.Age >= 12 years; within past year
    • Member has bilateral nasal polyposis and persistent symptoms despite at least 4 weeks of intranasal corticosteroid therapy; qualifying prior surgery or systemic corticosteroid history; an objective polyp finding; qualifying symptoms; and will continue daily intranasal corticosteroid therapy.Intranasal corticosteroid >= 4 weeks; Meltzer score >= 2 in both nostrils or total NPS >= 5 with >= 2 per nostril

    Eosinophilic esophagitis — initial therapy criteria

    All EoE initial-therapy criteria must be met.

    Member is at least 1 year old and weighs at least 15 kg; has esophageal dysfunction symptoms; has biopsy-confirmed EoE with at least 15 intraepithelial eosinophils per high-power field; and has inadequate response to a proton pump inhibitor or swallowed topical corticosteroid unless contraindicated or not tolerated.Age >= 1 year; weight >= 15 kg; biopsy count >= 15 eosinophils/high-power field

    Prurigo nodularis — qualifying initial therapy pathways

    Prurigo nodularis has TWO qualifying initial-therapy pathways.

    ONE of

    • Member is at least 18 years old and previously received a biologic indicated for prurigo nodularis within the past year.Age >= 18 years; within past year
    • Member is at least 18 years old, has pruritus for at least 6 weeks, repeated itch-scratch behavior, at least 20 nodular lesions, and qualifying inadequate response, intolerance, or clinical reason to avoid specified therapy.Pruritus >= 6 weeks; >= 20 nodular lesions

    Chronic obstructive pulmonary disease — qualifying initial therapy pathways

    COPD has TWO qualifying initial-therapy pathways.

    ONE of

    • Member is at least 18 years old and previously received a biologic indicated for COPD within the past year.Age >= 18 years; within past year
    • Member has spirometrically confirmed COPD, classic signs or symptoms, absolute blood eosinophils of at least 300 cells per microliter before treatment, qualifying exacerbations within the last year, qualifying maintenance inhaled therapy, and will continue maintenance COPD treatment with Dupixent.FEV1/FVC < 0.7; eosinophils >= 300 cells/microliter; 2 moderate or 1 severe exacerbation

    Chronic spontaneous urticaria — qualifying initial therapy pathways

    CSU has TWO qualifying initial-therapy pathways.

    ONE of

    • Member is at least 12 years old and previously received a biologic indicated for CSU within the past year.Age >= 12 years; within past year
    • Member remains symptomatic despite up-dosing a second-generation H1 antihistamine for at least 2 weeks, has been evaluated for alternative causes, and has spontaneous wheals, angioedema, or both for at least 6 weeks.H1 antihistamine up-dosing >= 2 weeks; symptoms >= 6 weeks

    Immune checkpoint inhibitor-related toxicity — qualifying initial therapy pathways

    ONE of the following immune checkpoint inhibitor-related toxicity pathways must be met.

    ANY of the following

    • Severe grade 3 pruritus has not responded to gabapentinoids for one month.G3 pruritus; 1-month gabapentinoid trial
    • Dupixent is used as additional therapy for bullous pemphigoid with moderate grade 2 bullous dermatitis, or for severe grade 3 or life-threatening grade 4 bullous dermatitis.G2 bullous pemphigoid, or G3/G4 bullous dermatitis
    Member is at least 6 months of age and achieves or maintains positive clinical response, evidenced by low disease activity or improvement in redness, itching, or oozing/crusting.Age >= 6 months

    Asthma — continuation criteria

    Authorization of 12 months may be granted after prior HMSA/CVS authorization when ALL of the following are met.

    ALL of the following

    • Asthma control has improved, demonstrated by reduced frequency or severity of symptoms or exacerbations, or reduced daily maintenance oral corticosteroid dose.
    • Member will continue an inhaled corticosteroid and an additional controller in combination with Dupixent.

    Chronic rhinosinusitis with nasal polyposis — continuation criteria

    Authorization of 12 months may be granted after prior HMSA/CVS authorization when ALL of the following are met.

    ALL of the following

    • Member is at least 12 years old and has achieved or maintained positive clinical response, including improvement in nasal congestion, polyp size, smell, rhinorrhea, inflammation, facial pressure or pain, or corticosteroid use.Age >= 12 years
    • Member will continue daily intranasal corticosteroid therapy unless contraindicated or not tolerated.

    Eosinophilic esophagitis — continuation criteria

    Authorization of 12 months may be granted after prior HMSA/CVS authorization.

    Member is at least 1 year old, weighs at least 15 kg, and has achieved or maintained positive clinical response evidenced by improvement in dysphagia, heartburn, chest pain, or emesis.Age >= 1 year; weight >= 15 kg

    Prurigo nodularis — continuation criteria

    Authorization of 12 months may be granted after prior HMSA/CVS authorization.

    Member is at least 18 years old and has achieved or maintained positive clinical response evidenced by low disease activity, or reduced pruritus intensity with improvement in the extent and severity of nodular lesions.Age >= 18 years

    Chronic obstructive pulmonary disease — continuation criteria

    Authorization of 12 months may be granted after prior HMSA/CVS authorization when ALL of the following are met.

    ALL of the following

    • Member is at least 18 years old and has achieved or maintained positive clinical response or disease stabilization, evidenced by decreased exacerbations, improved pre-bronchodilator FEV1, or stabilization of disease.Age >= 18 years
    • Member will continue maintenance COPD treatment, such as ICS with LAMA and LABA, or LAMA and LABA, in combination with Dupixent.

    Chronic spontaneous urticaria — continuation criteria

    Authorization of 12 months may be granted after prior HMSA/CVS authorization.

    Member is at least 12 years old and has experienced positive clinical response since initiation of therapy, such as improved symptoms or decreased weekly urticaria activity score (UAS7).Age >= 12 years

    Immune checkpoint inhibitor-related toxicities — continuation criteria

    Authorization of 12 months may be granted after prior HMSA/CVS authorization when the applicable pathway is met.

    ANY of the following

    • Member was previously authorized for severe grade 3 pruritus and achieves or maintains positive clinical response evidenced by low disease activity or improvement in signs and symptoms.G3 pruritus
    • Member was previously authorized for bullous dermatitis and achieves or maintains positive clinical response, with either moderate grade 2 bullous dermatitis when the diagnosis is bullous pemphigoid, or severe grade 3 or life-threatening grade 4 bullous dermatitis.G2 bullous pemphigoid, or G3/G4 bullous dermatitis
    Eosinophilic asthma
    CRSwNP Meltzer Clinical Score
    Meltzer Clinical ScoreAt least 2 in both nostrils
    Assessment typeObjective finding for bilateral nasal polyposis
    Applicable conditionChronic rhinosinusitis with nasal polyposis
    CRSwNP endoscopic nasal polyp score
    Total nasal polyp scoreAt least 5 total
    Per-nostril minimumAt least 2 for each nostril
    Assessment typeEndoscopic nasal polyp score
    EoE biopsy eosinophil count
    Biopsy thresholdAt least 15 intraepithelial esophageal eosinophils per high-power field
    Confirmation methodEsophageal biopsy
    Applicable conditionEosinophilic esophagitis
    Prurigo nodularis lesion count
    Lesion thresholdAt least 20 nodular lesions
    Associated symptomPruritus lasting at least 6 weeks
    Disease featureHistory or signs of a repeated itch-scratch cycle
    COPD eosinophil count
    Eosinophil thresholdAt least 300 cells per microliter before initiating therapy
    MeasurementAbsolute blood eosinophil count
    Applicable conditionChronic obstructive pulmonary disease with an eosinophilic phenotype
    COPD post-bronchodilation spirometry
    Spirometry thresholdFEV1/FVC less than 0.7
    TimingMeasured post-bronchodilation
    PurposeConfirmation of COPD diagnosis
  4. Hematologist or oncologist: immune checkpoint inhibitor-related toxicity.
  5. Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Dupixent. Submit the request using the HMSA specialty drug policy fax form available through the HMSA medical specialty drug policy website.

    Billing Rule

    Dosing Limits May Apply

    Approval may be subject to dosing limits consistent with FDA-approved labeling, accepted compendia, and evidence-based practice guidelines.

    Step Therapy

    Atopic Dermatitis: Required Topical Therapy

    For atopic dermatitis, document inadequate response to required topical therapies or why those therapies are not advisable.

    • High- or super-high-potency topical corticosteroid for 2 consecutive weeks.
    • Topical calcineurin inhibitor, such as tacrolimus, for 6 consecutive weeks.
    • Topical JAK inhibitor, such as Opzelura, for 8 consecutive weeks.
    • Topical aryl hydrocarbon receptor agonist, such as Vtama, for 8 consecutive weeks.
    • The required topical treatments may be avoided when clinically inappropriate because of contraindication, prior intolerance, age-related potency concerns, or other documented clinical reasons.
    Step Therapy

    Asthma: Optimized Controller Therapy

    For asthma, document inadequate control despite optimized controller therapy and continued use of maintenance treatment with Dupixent.

    • Medium- to high-dose inhaled corticosteroid plus an additional controller, when the eosinophilic phenotype pathway is used.
    • High-dose inhaled corticosteroid, additional controller, and oral glucocorticoid therapy for oral corticosteroid-dependent asthma.
    • Additional controllers may include a LABA, LAMA, leukotriene modifier, or sustained-release theophylline.
    • For the oral corticosteroid-dependent pathway, inhaled corticosteroid and additional controller therapy should generally have been used for at least 3 months, with oral glucocorticoids used most days during the prior 6 months.
    • Member must continue inhaled corticosteroid and additional controller therapy with Dupixent.
    Step Therapy

    CRSwNP: Required Prior Treatment

    For CRSwNP, document bilateral nasal polyposis and chronic sinus symptoms despite intranasal corticosteroid treatment for at least 4 weeks, unless contraindicated or not tolerated, along with qualifying prior treatment history.

    • Prior sino-nasal surgery; or ineffective systemic corticosteroid treatment within the last 2 years, unless contraindicated or not tolerated.
    • Member must continue a daily intranasal corticosteroid with Dupixent unless contraindicated or not tolerated.
    Step Therapy

    EoE: Required Prior Treatment

    For EoE, document an inadequate response to a proton pump inhibitor or swallowed topical corticosteroid therapy, unless the therapy was contraindicated or not tolerated.

    • Examples of swallowed topical corticosteroids include budesonide and fluticasone powder or suspension for inhalation.
    Step Therapy

    Prurigo Nodularis: Required Prior Treatment

    For prurigo nodularis, document an inadequate response to, or intolerance or clinical reason to avoid, specified topical, phototherapy, or systemic treatment.

    • Prior therapies may include medium- to super-high-potency topical corticosteroid, topical calcineurin inhibitor, phototherapy such as UVB or PUVA, methotrexate, or cyclosporine.
    • When relying on avoidance, document intolerance or clinical reasons involving topical corticosteroid/topical calcineurin inhibitor therapy or methotrexate/cyclosporine therapy.
    Step Therapy

    COPD: Maintenance Therapy Requirement

    For COPD, document current maintenance inhaled therapy before and during Dupixent treatment.

    • Current inhaled triple therapy: ICS, LAMA, and LABA; or
    • Current LAMA and LABA therapy when the member has a contraindication to ICS.
    • Member must continue maintenance COPD treatment, such as ICS with LAMA and LABA or LAMA and LABA, with Dupixent.
    Step Therapy

    CSU: Required Antihistamine Therapy

    For CSU, document persistent symptoms despite up-dosing a second-generation H1 antihistamine according to applicable EAACI/GA2LEN/EuroGuiDerm/APAAACI guidelines.

    • Up-dosed therapy must generally be documented for at least 2 weeks.
    • Examples include cetirizine, fexofenadine, levocetirizine, or loratadine.
    Step Therapy

    Checkpoint Toxicity: Prior Gabapentinoid Therapy

    For severe (grade 3) pruritus related to immune checkpoint inhibitor toxicity, document no response to gabapentinoid therapy after one month before requesting Dupixent.

    • This requirement applies to the severe G3 pruritus pathway.
    Documentation Required

    General Clinical Documentation

    Provide chart notes, medical records, or claims history sufficient to establish the applicable diagnosis, severity, prior treatment, response, and continuation requirements.

    • Include drug, dose, frequency, duration, and response when prior medication history is required.
    • If a required therapy is not advisable, document the clinical reason, such as contraindication or intolerance.
    • For continuation requests, document positive clinical response unless the applicable criterion specifies otherwise.
    Documentation Required

    Atopic Dermatitis: Required Documentation

    Atopic dermatitis documentation must describe the affected areas and body surface area, where applicable, and support prior therapy history and response.

    • Initial requests: affected area(s) and body surface area; symptoms such as pruritus may also be documented.
    • List prior topical corticosteroids, topical calcineurin inhibitors, topical JAK inhibitors, topical aryl hydrocarbon receptor agonists, biologics, or targeted synthetic drugs, including dosage, duration, and response.
    • Document why therapy is not advisable when applicable.
    • Continuation requests: positive clinical response.
    Documentation Required

    Asthma: Required Documentation

    Asthma documentation must support the phenotype, prior treatment, and current disease control.

    • Provide the pretreatment blood eosinophil count, where applicable.
    • List prior medications with drug, dose, frequency, and duration.
    • For continuation, document improvement in asthma control.
    Documentation Required

    CRSwNP: Required Documentation

    CRSwNP documentation must establish objective disease findings, symptoms, and prior treatment.

    • Provide nasal endoscopy, anterior rhinoscopy, or CT findings, including polyp location and size where available.
    • Provide Meltzer Clinical Score or endoscopic nasal polyp score, where applicable.
    • List prior medications with drug, dose, frequency, and duration, and document why therapy is not advisable when applicable.
    • For continuation, document positive clinical response.
    Documentation Required

    EoE: Required Documentation

    EoE documentation must confirm the diagnosis and support prior treatment and response.

    • Provide endoscopic biopsy details, including the intraepithelial esophageal eosinophil count.
    • List prior therapies and document why therapy is not advisable when applicable.
    • For continuation, document positive clinical response.
    Documentation Required

    Prurigo Nodularis: Required Documentation

    Prurigo nodularis documentation must establish the characteristic symptoms and lesions and support prior therapy history.

    • Document symptoms such as pruritus and nodular lesions.
    • List previous therapies and response, including topical, phototherapy, or systemic treatment.
    • If therapy is not advisable, document the clinical reason.
    • For continuation, document positive clinical response.
    Documentation Required

    COPD: Required Documentation

    COPD documentation must establish objective airflow obstruction, disease features, eosinophilic phenotype, exacerbation history, and treatment history.

    • Document classic COPD signs and symptoms.
    • Provide prior medication history and response, or the clinical reason therapy is not advisable.
    • Provide the absolute pretreatment blood eosinophil count.
    • Document moderate or severe exacerbations within the last year.
    • For continuation, document positive clinical response.
    Documentation Required

    CSU: Required Documentation

    CSU documentation must establish prior antihistamine treatment and response and support continued benefit.

    • Provide medication history, including prior treatment and response.
    • For continuation, document positive response to therapy.
    Documentation Required

    Immune Checkpoint Toxicity: Required Documentation

    For immune checkpoint inhibitor-related toxicity, continuation requests must document ongoing benefit and evidence of the treated toxicity.

    • Provide chart notes or medical records supporting positive clinical response.
    • For bullous dermatitis, document the applicable diagnosis and severity when relevant.
    Documentation Required

    Reauthorization: Clinical Response and Treatment Documentation

    Reauthorization requires documentation that the member was previously authorized by HMSA/CVS and has achieved or maintained a positive clinical response, together with any indication-specific treatment continuation requirement.

    • Atopic dermatitis: low disease activity or improved redness, itching, oozing, or crusting.
    • Asthma: reduced symptom or exacerbation frequency/severity or reduced daily maintenance oral corticosteroid dose, with continued inhaled corticosteroid and additional controller.
    • CRSwNP: improved congestion, polyp size, smell, rhinorrhea, inflammation, hyposmia, facial pressure/pain, or corticosteroid use, with continued daily intranasal corticosteroid unless contraindicated or not tolerated.
    • EoE: improved dysphagia, heartburn, chest pain, or emesis.
    • Prurigo nodularis: clear or almost clear skin or reduced pruritus and improved nodular lesions.
    • COPD: fewer exacerbations, improved pre-bronchodilator FEV1, or disease stabilization, with continued maintenance COPD treatment.
    • CSU: improved symptoms or decreased UAS7.
    • Immune checkpoint toxicity: low disease activity or improved signs and symptoms, including the applicable bullous dermatitis severity pathway.
    Prior Authorization

    HMSA Specialty Drug Policy Fax Form

    Submit prior authorization and reauthorization requests using the HMSA specialty drug policy fax form available on the HMSA medical specialty drug policy website.

    • Include all indication-specific clinical documentation required for the requested review.
    Note

    General Approval Requirements and Limitations

    Coverage is available only when all applicable approval criteria are met and the member has no exclusion to the prescribed therapy. Dupixent is not indicated for acute bronchospasm, status asthmaticus, or other forms of urticaria.

    • FDA-approved and applicable compendial indications may be covered when requirements are satisfied.
    • For all indications, the member cannot use Dupixent concomitantly with another biologic drug or targeted synthetic drug for the same indication.
    • Pulmonary patients who smoke or vape should be counseled regarding associated harms and cessation options.
    Denial Risk

    Atopic Dermatitis: Criteria Not Met

    Atopic dermatitis requests may be denied when the member does not meet the applicable age, severity, body-area, prior-treatment, or clinical-reason criteria.

    • Member is younger than 6 months.
    • For the moderate-to-severe pathway, affected body surface area is below 10% and no qualifying crucial body area is affected.
    • Required topical therapies were not tried for the specified durations, did not have an inadequate response, and are not documented as clinically inadvisable.
    • A qualifying prior biologic or systemic targeted synthetic drug trial within the past 180 days is not documented when that pathway is used.
    Denial Risk

    Asthma: Criteria Not Met

    Asthma requests may be denied when the member does not meet the applicable age, uncontrolled-disease, phenotype, treatment, or continuation requirements.

    • Member is younger than 6 years.
    • No qualifying asthma exacerbation, hospitalization/emergency visit, or poor symptom control is documented within the past year.
    • The required eosinophil threshold and optimized controller therapy are not documented for the eosinophilic pathway.
    • The required high-dose inhaled corticosteroid, additional controller, and oral glucocorticoid use are not documented for the oral corticosteroid-dependent pathway.
    • The member will not continue maintenance asthma treatment with Dupixent.
    Denial Risk

    CRSwNP: Criteria Not Met

    CRSwNP requests may be denied when the member does not meet the applicable age, disease, prior-treatment, objective findings, symptom, or continuation requirements.

    • Member is younger than 12 years.
    • Bilateral polyposis and chronic symptoms despite at least 4 weeks of intranasal corticosteroid treatment are not documented, absent a qualifying contraindication or intolerance.
    • Required prior sino-nasal surgery or ineffective systemic corticosteroid treatment within the last 2 years is not documented.
    • Qualifying objective polyp findings or symptom combinations are not documented.
    • The member will not continue daily intranasal corticosteroid treatment when required.
    Denial Risk

    EoE: Criteria Not Met

    EoE requests may be denied when the member does not meet the applicable age, weight, symptom, biopsy, or prior-treatment requirements.

    • Member is younger than 1 year or weighs less than 15 kg.
    • Symptoms of esophageal dysfunction are not documented.
    • Biopsy does not confirm at least 15 intraepithelial esophageal eosinophils per high-power field.
    • Inadequate response to a proton pump inhibitor or swallowed topical corticosteroid is not documented, and no qualifying contraindication or intolerance is established.
    Denial Risk

    Prurigo Nodularis: Criteria Not Met

    Prurigo nodularis requests may be denied when the member does not meet the applicable age, symptom, lesion, or prior-treatment requirements.

    • Member is younger than 18 years.
    • Pruritus lasting at least 6 weeks, a repeated itch-scratch cycle, or at least 20 nodular lesions is not documented.
    • An inadequate response to a qualifying topical, phototherapy, methotrexate, or cyclosporine therapy is not documented.
    • Qualifying intolerance or clinical reason to avoid the required therapies is not documented.
    Denial Risk

    COPD: Criteria Not Met

    COPD requests may be denied when the member does not meet the applicable age, diagnostic, eosinophil, exacerbation, treatment, or continuation requirements.

    • Member is younger than 18 years.
    • Post-bronchodilator FEV1/FVC is not less than 0.7 or spirometric confirmation is not provided.
    • Classic COPD symptoms, an absolute pretreatment eosinophil count of at least 300 cells per microliter, or qualifying exacerbations are not documented.
    • The member is not receiving inhaled triple therapy or LAMA/LABA therapy with a documented ICS contraindication.
    • The member will not continue maintenance COPD treatment with Dupixent.
    Denial Risk

    CSU: Criteria Not Met

    CSU requests may be denied when the member does not meet the applicable age, antihistamine, evaluation, or duration-of-disease requirements.

    • Member is younger than 12 years.
    • Persistent symptoms despite guideline-directed up-dosing of a second-generation H1 antihistamine for at least 2 weeks are not documented.
    • Evaluation for other causes of wheals or angioedema is not documented.
    • Spontaneous wheals, angioedema, or both have not been present for at least 6 weeks.
    Denial Risk

    Immune Checkpoint Toxicity: Criteria Not Met

    Immune checkpoint inhibitor-related toxicity requests may be denied when the requested use does not meet the specified severity or prior-treatment criteria.

    • For severe G3 pruritus, no failure to respond to gabapentinoids after one month is documented.
    • For bullous pemphigoid, moderate G2 bullous dermatitis is not documented.
    • For other bullous dermatitis, severe G3 or life-threatening G4 disease is not documented.
    Denial Risk

    Concomitant Biologic or Targeted Synthetic Therapy

    Dupixent cannot be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • Requests may be denied or coverage may be restricted when concurrent same-indication biologic or targeted synthetic therapy is planned.
    Denial Risk

    Failure to Meet Reauthorization Criteria

    Reauthorization may be denied when the member was not previously authorized by HMSA/CVS, positive clinical response is not demonstrated, or required maintenance treatment is not continued.

    • Atopic dermatitis: no low disease activity or improvement in signs and symptoms.
    • Asthma: no documented improvement in control or no continued inhaled corticosteroid and additional controller.
    • CRSwNP: no positive clinical response or no continued daily intranasal corticosteroid when required.
    • EoE: no improvement in signs or symptoms.
    • Prurigo nodularis: no low disease activity or improvement in pruritus and lesions.
    • COPD: no positive response or stabilization, or no continued maintenance therapy.
    • CSU: no positive clinical response, such as improved symptoms or decreased UAS7.
    • Immune checkpoint toxicity: no positive response or no evidence supporting the applicable toxicity pathway.
    Confirms the COPD diagnosis
    Eosinophilic esophagitis biopsy confirmation
    Biopsy thresholdAt least 15 intraepithelial esophageal eosinophils per high-power field
    SpecimenEsophageal biopsy
    Diagnostic useConfirms eosinophilic esophagitis
    Chronic spontaneous urticaria
    DurationSpontaneous symptoms for at least 6 weeks
    SymptomsSpontaneous wheals, angioedema, or both
    EvaluationOther causes of wheals or angioedema must be evaluated, including bradykinin-related angioedema and interleukin-1-associated urticarial syndromes
    Maintenance asthma treatments
    Required inhaled therapyAn inhaled corticosteroid
    Additional treatmentAn additional controller
    Continuation useBoth treatments continue in combination with Dupixent
    Daily intranasal corticosteroid
    Background treatmentDaily intranasal corticosteroid
    Continuation requirementContinue while treated with Dupixent for CRSwNP
    ExceptionNot required when contraindicated or not tolerated
    Toxicity grades
    G2Moderate toxicity; for bullous pemphigoid, moderate bullous dermatitis qualifies
    G3Severe toxicity; severe pruritus or severe bullous dermatitis may qualify
    G4Life-threatening toxicity; life-threatening bullous dermatitis may qualify
    Dupixent
    Dupixent 12-month authorization quantity limit
    Authorization period12 months per course
    Applicable indicationsChronic obstructive pulmonary disease and immune checkpoint inhibitor-related toxicity
    MedicationDupixent
    Dupixent dosing limits
    Dosing standardDosing limits may apply
    Applicable sourcesFDA-approved labeling, accepted compendia, and evidence-based practice guidelines
    MedicationDupixent (dupilumab)